Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)-Reference-Cited by-同舟云学术

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Published:2021-12 Issue:6 Volume:4 Page:963-970
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Crumbaker Megan^ORCID,Pathmanandavel Sarennya,Yam Andrew O.^ORCID,Nguyen Andrew,Ho Bao,Chan Lyn,Ende Jesse A.,Rofe Christopher,Kongrak Kamonwan,Kwan Edmond M.^ORCID,Azad Arun A.,Sharma Shikha,Pugh Trevor J.,Danesh Arnavaz,Keane Joanne,Eu Peter^ORCID,Joshua Anthony M.^ORCID,Emmett Louise

Funder

Noxopharm

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference29 articles.

1. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression;Emmett;Clin Genitourin Cancer,2019

2. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018

3. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer;Violet;J Nucl Med,2020

4. TheraP: a randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603);Hofman;J Clin Oncol,2020

5. Phenoxodiol—an isoflavone analog—induces apoptosis in chemoresistant ovarian cancer cells;Kamsteeg;Oncogene,2003

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. [ ⁶⁸ Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer;Expert Review of Molecular Diagnostics;2024-07-02

3. Anti-Cancer Effects of Soy Isoflavones against Cancer by Radiosensitizing Properties: A Systematic Review;Current Cancer Therapy Reviews;2024-06-21

4. Development of a Visually Calculated SUV_mean(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to¹⁷⁷Lu-PSMA Therapy: Comparison with Quantitative SUV_meanand Patient Outcomes;Journal of Nuclear Medicine;2024-04-18

5. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer;European Urology;2024-04